Mogelijk gemaakt door 
Translate
Translate
|
For immediate release |
11 July 2024 |
ANGLE plc ("the Company")
Result of 2024 Annual General Meeting
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, announces that at the Annual General Meeting of the Company held earlier today, all resolutions were duly passed.
For further information:
|
ANGLE plc |
+44 (0) 1483 343434 |
|
Andrew Newland, Chief Executive Ian Griffiths, Finance Director |
|
|
Berenberg (NOMAD and Broker) Toby Flaux, Ciaran Walsh, Milo Bonser |
+44 (0) 20 3207 7800 |
|
FTI Consulting Simon Conway, Ciara Martin Matthew Ventimiglia (US) |
+44 (0) 203 727 1000 +1 (212) 850 5624 |
Notes for editors
About ANGLE plc
ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected circulating tumour cell (CTC) harvesting technology known as the Parsortix® PC1 system enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.
ANGLE's commercial businesses are focusing on diagnostic products and clinical services. Diagnostic products include the Parsortix® system and associated consumables. The clinical services business is offered through ANGLE's GCP-compliant laboratories in the UK. Services include custom made assay development and clinical trial testing for pharma.
Over 90 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com
